COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
| Title: | COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) |
|---|---|
| Authors: | Pagano L.; Salmanton-Garcia J.; Marchesi F.; Busca A.; Corradini P.; Hoenigl M.; Klimko N.; Koehler P.; Pagliuca A.; Passamonti F.; Verga L.; Visek B.; Ilhan O.; Nadali G.; Weinbergerova B.; Cordoba-Mascunano R.; Marchetti M.; Collins G. P.; Farina F.; Cattaneo C.; Cabirta A.; Gomes-Silva M.; Itri F.; van Doesum J.; Ledoux M. -P.; Cernan M.; Jaksic O.; Duarte R. F.; Magliano G.; Omrani A. S.; Fracchiolla N. S.; Kulasekararaj A.; Valkovic T.; Poulsen C. B.; Machado M.; Glenthoj A.; Stoma I.; Racil Z.; Piukovics K.; Navratil M.; Emarah Z.; Sili U.; Maertens J.; Blennow O.; Bergantim R.; Garcia-Vidal C.; Prezioso L.; Guidetti A.; del Principe M. I.; Popova M.; de Jonge N.; Ormazabal-Velez I.; Fernandez N.; Falces-Romero I.; Cuccaro A.; Meers S.; Buquicchio C.; Antic D.; Al-Khabori M.; Garcia-Sanz R.; Biernat M. M.; Tisi M. C.; Sal E.; Rahimli L.; Colovic N.; Schonlein M.; Calbacho M.; Tascini C.; Miranda-Castillo C.; Khanna N.; Mendez G. -A.; Petzer V.; Novak J.; Besson C.; Dulery R.; Lamure S.; Nucci M.; Zambrotta G.; Zak P.; Seval G. C.; Bonuomo V.; Mayer J.; Lopez-Garcia A.; Sacchi M. V.; Booth S.; Ciceri F.; Oberti M.; Salvini M.; Izuzquiza M.; Nunes-Rodrigues R.; Ammatuna E.; Obr A.; Herbrecht R.; Nunez-Martin-Buitrago L.; Mancini V.; Shwaylia H.; Sciume M.; Essame J.; Nygaard M.; Batinic J.; Gonzaga Y.; Regalado-Artamendi I.; Karlsson L. K.; Shapetska M.; Hanakova M.; El-Ashwah S.; Borbenyi Z.; Colak G. M.; Nordlander A.; Dragonetti G.; Maraglino A. M. E.; Rinaldi A.; De Ramon-Sanchez C.; Cornely O. A.; Finizio O.; Fazzi R.; Sapienza G.; Chauchet A.; Van Praet J.; Prattes J.; Dargenio M.; Rossi C.; Shirinova A.; Malak S.; Tafuri A.; Ommen H. -B.; Bologna S.; Khedr R. A.; Choquet S.; Joly B.; Ceesay M. M.; Philippe L.; Kho C. S.; Desole M.; Tsirigotis P.; Otasevic V.; Borducchi D. M. M.; Antoniadou A.; Gaziev J.; Almaslamani M. A.; Garcia-Pouton N.; Paterno G.; Torres-Lopez A.; Tarantini G.; Mellinghoff S.; Grafe S.; Borschel N.; Passweg J.; Merelli M.; Barac A.; Wolf D.; Shaikh M. U.; Thieblemont C.; Bernard S.; Funke V. A. M.; Daguindau E.; Khostelidi S.; Nucci F. M.; Martin-Gonzalez J. -A.; Landau M.; Soussain C.; Laureana C.; Lacombe K.; Kohn M.; Aliyeva G.; Piedimonte M.; Fouquet G.; Rego M.; Hoell-Neugebauer B.; Cartron G.; Pinto F.; Alburquerque A. M.; Passos J.; Yilmaz A. F.; Redondo-Izal A. -M.; Altuntas F.; Heath C.; Kolditz M.; Schalk E.; Guolo F.; Karthaus M.; Della Pepa R.; Vinh D.; Noel N.; Deau Fischer B.; Drenou B.; Mitra M. E.; Meletiadis J.; Bilgin Y. M.; Jindra P.; Espigado I.; Drgona L.; Serris A.; Di Blasi R.; Ali N. |
| Contributors: | L. Pagano; J. Salmanton-Garcia; F. Marchesi; A. Busca; P. Corradini; M. Hoenigl; N. Klimko; P. Koehler; A. Pagliuca; F. Passamonti; L. Verga; B. Visek; O. Ilhan; G. Nadali; B. Weinbergerova; R. Cordoba-Mascunano; M. Marchetti; G.P. Collin; F. Farina; C. Cattaneo; A. Cabirta; M. Gomes-Silva; F. Itri; J. van Doesum; M.-. Ledoux; M. Cernan; O. Jaksic; R.F. Duarte; G. Magliano; A.S. Omrani; N.S. Fracchiolla; A. Kulasekararaj; T. Valkovic; C.B. Poulsen; M. Machado; A. Glenthoj; I. Stoma; Z. Racil; K. Piukovic; M. Navratil; Z. Emarah; U. Sili; J. Maerten; O. Blennow; R. Bergantim; C. Garcia-Vidal; L. Prezioso; A. Guidetti; M.I. del Principe; M. Popova; N. de Jonge; I. Ormazabal-Velez; N. Fernandez; I. Falces-Romero; A. Cuccaro; S. Meer; C. Buquicchio; D. Antic; M. Al-Khabori; R. Garcia-Sanz; M.M. Biernat; M.C. Tisi; E. Sal; L. Rahimli; N. Colovic; M. Schonlein; M. Calbacho; C. Tascini; C. Miranda-Castillo; N. Khanna; G.-. Mendez; V. Petzer; J. Novak; C. Besson; R. Dulery; S. Lamure; M. Nucci; G. Zambrotta; P. Zak; G.C. Seval; V. Bonuomo; J. Mayer; A. Lopez-Garcia; M.V. Sacchi; S. Booth; F. Ciceri; M. Oberti; M. Salvini; M. Izuzquiza; R. Nunes-Rodrigue; E. Ammatuna; A. Obr; R. Herbrecht; L. Nunez-Martin-Buitrago; V. Mancini; H. Shwaylia; M. Sciume; J. Essame; M. Nygaard; J. Batinic |
| Publisher Information: | BioMed Central |
| Publication Year: | 2021 |
| Collection: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| Subject Terms: | COVID-19; EHA; Epidemiology; Hematological malignancie; Pandemic; Settore MED/15 - Malattie del Sangue |
| Description: | Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced ... |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/34649563; info:eu-repo/semantics/altIdentifier/wos/WOS:000707341700001; volume:14; issue:1; firstpage:1; lastpage:15; numberofpages:15; journal:JOURNAL OF HEMATOLOGY & ONCOLOGY; https://hdl.handle.net/2434/891943 |
| DOI: | 10.1186/s13045-021-01177-0 |
| Availability: | https://hdl.handle.net/2434/891943; https://doi.org/10.1186/s13045-021-01177-0 |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.BEF98D34 |
| Database: | BASE |